Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 231

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double‐blind, placebo‐controlled study

Haas, Magali, DelBello, Melissa P, Pandina, Gahan, Kushner, Stuart, Van Hove, Ilse, Augustyns, Ilse, Quiroz, Jorge, Kusumakar, Vivek·2009·Bipolar Disorders

Abstract

Objectives: To evaluate the efficacy, safety, and tolerability of risperidone monotherapy for the treatment of an acute mixed or manic episode in children and adolescents with bipolar I disorder. Methods: This randomized, placebo‐controlled, double‐blind, 3‐arm study (N = 169) included children and adolescents (ages 10–17 years) with a DSM‐IV diagnosis of bipolar I disorder, experiencing a manic or mixed episode. Study participants were randomized to placebo (n = 58), risperidone 0.5–2.5 mg/day (n = 50), or risperidone 3–6 mg/day (n = 61) for 3 weeks. The primary efficacy measure was change in Young Mania Rating Scale (YMRS) total score from baseline to end point. Safety assessments included adverse event (AE) monitoring and scores on extrapyramidal symptom rating scales. Results: Improvement in mean YMRS total score was significantly greater in risperidone‐treated subjects than in placebo‐treated subjects [mean change (SD) −9.1 (11.0) for placebo; −18.5 (9.7) for risperidone 0.5–2.5 mg (p < 0.001); −16.5 (10.3) for risperidone 3–6 mg (p < 0.001)]. The most common risperidone‐associated AEs were somnolence, headache, and fatigue. Mean (SD) weight gain was 0.7 (1.9) kg, 1.9 (1.7) kg, and 1.4 (2.4) kg in the placebo, risperidone 0.5–2.5 mg, and risperidone 3–6 mg groups, respectively, during this 3‐week study. Conclusions: At daily doses of 0.5–2.5 mg and 3–6 mg, risperidone was effective and well tolerated in children and adolescents experiencing acute manic or mixed episodes of bipolar I disorder. Results indicate that risperidone 0.5–2.5 mg has a better benefit–risk profile than risperidone 3–6 mg.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1399-5618.2009.00750.x

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 231

Metadata

Authors
Haas, M., DelBello, M. P., Pandina, G., Kushner, S., Van Hove, I., Augustyns, I., Quiroz, J., & Kusumakar, V.
Venue
Bipolar Disorders
Publisher
Wiley
Published
2009-10-14
Volume
11
Issue
7
Pages
687-700
ISSN
  • 1398-5647 (ISSN-L)
  • 1399-5618
OpenAlex
W2072020486
Cited by
231
References
8
FWCI
10.52
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double‐blind, placebo‐controlled study. https://app.cochat.ai/papers/10.1111/j.1399-5618.2009.00750.x
The paper
Haas, M., DelBello, M. P., Pandina, G., Kushner, S., Van Hove, I., Augustyns, I., Quiroz, J., & Kusumakar, V. (2009). Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double‐blind, placebo‐controlled study. Bipolar Disorders. https://doi.org/10.1111/j.1399-5618.2009.00750.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.